Yencilek Faruk, Erturhan Sakip, Canguven Onder, Koyuncu Hakan, Erol Bulent, Sarica Kemal
Department of Urology, Yeditepe University Medical Faculty, Devlet Yolu Ankara Cad. 102/104, 34752, Kozyatagi, Istanbul, Turkey.
Urol Res. 2010 Jun;38(3):195-9. doi: 10.1007/s00240-010-0257-6. Epub 2010 Feb 25.
The objective of this study is to assess the efficacy of an alpha-1 adrenergic receptor blocking agent on the spontaneous passage of proximal ureteral calculi < or =10 mm. 92 patients having single radio-opaque proximal ureteral stone < or =10 mm were randomized into two groups. Group 1 patients (n = 50) were followed with classical conservative approach and patients in Group 2 (n = 42) additionally received tamsulosin, 0.4 mg/day during 4 weeks follow-up. The stone passage rates, stone expulsion time, VAS score, change in colic episodes, and hospital re-admission rates for colicky pain were compared. The patients were furthermore stratified according to stone diameters <5 and 5-10 mm. The data of these subgroups were also compared. Stone expulsion rates showed statistically significant difference between tamsulosin receivers and non-receivers (35.7 vs 30%, p = 0.04). Time to stone expulsion period was also shortened in those receiving tamsulosin (8.4 +/- 3.3 vs 11.6 +/- 4.1 days, p = 0.015). Likewise, the mean VAS score and renal colic episodes during follow-up period were significantly diminished in Group 2 patients (4.5 +/- 2.3 vs 8.8 +/- 2.9, p < 0.01 and 66.6 vs 36%, p = 0.001, respectively). Among the stones <5 mm, tamsulosin receiving patients had higher spontaneous passage rate (71.4 vs 50%, p < 0.001). The prominent effect of tamsulosin on the 5-10 mm stones was the relocation of the stones to a more distal part of ureter (39.3 vs 18.7%, p = 0.001). Administration of tamsulosin in the medical management of proximal ureteral calculi can facilitate the spontaneous passage rate in the stone <5 mm and the relocation of the stones between 5 and 10 mm to more distal part of the ureter.
本研究的目的是评估一种α-1肾上腺素能受体阻滞剂对直径小于或等于10毫米的近端输尿管结石自然排出的疗效。92例有单个不透X线的直径小于或等于10毫米的近端输尿管结石患者被随机分为两组。第1组患者(n = 50)采用传统保守方法进行随访,第2组患者(n = 42)在4周的随访期间额外服用坦索罗辛,每日0.4毫克。比较结石排出率、结石排出时间、视觉模拟评分(VAS)、绞痛发作次数的变化以及因绞痛再次入院的比率。此外,根据结石直径小于5毫米和5至10毫米对患者进行分层。还对这些亚组的数据进行了比较。坦索罗辛服用者和未服用者之间的结石排出率显示出统计学上的显著差异(35.7%对30%,p = 0.04)。服用坦索罗辛的患者结石排出期时间也缩短了(8.4±3.3天对11.6±4.1天,p = 0.015)。同样,第2组患者在随访期间的平均VAS评分和肾绞痛发作次数显著减少(分别为4.5±2.3对8.8±2.9,p < 0.01;66.6%对36%,p = 0.001)。在直径小于5毫米的结石中,服用坦索罗辛的患者有更高的自然排出率(71.4%对50%,p < 0.001)。坦索罗辛对5至10毫米结石的显著作用是使结石向输尿管更远端移位(39.3%对18.7%,p = 0.001)。在近端输尿管结石的药物治疗中使用坦索罗辛可提高直径小于5毫米结石的自然排出率,并使直径在5至10毫米之间的结石向输尿管更远端移位。